Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study

Article Oncology

The efficacy and safety of apatinib treatment for patients with advanced or recurrent biliary tract cancer: a retrospective study

Caiyun Nie et al.

Summary: Apatinib monotherapy or combination therapy can improve PFS in patients with advanced or recurrent BTC, and adverse reactions can be well tolerated.

BMC CANCER (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Oncology

Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial

Dapeng Li et al.

Summary: Anlotinib demonstrated significant improvement in progression-free survival and objective response rate in patients with MTC, with a higher incidence of treatment-related adverse events. However, it showed relatively reliable safety profile in this population.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised multicentre, double-blind, phase 3 trial

Rui-Hua Xu et al.

Summary: The RAINBOW-Asia study conducted in China and other Asian countries showed that the combination of ramucirumab and paclitaxel is effective and safe for patients with advanced gastric or GEJ adenocarcinoma in the Asian population, predominantly Chinese, as a second-line treatment option.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2021)

Add to Collection

Article Oncology

Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC

Tianqing Chu et al.

Summary: Although the evidence supporting the combination of immune checkpoint inhibitors and antiangiogenic tyrosine kinase inhibitors in treatment-naive patients with advanced NSCLC is insufficient, this report presented the efficacy and safety of sintilimab combined with anlotinib in a phase 1b trial. The study showed promising results with a high objective response rate and disease control rate, as well as manageable treatment-related adverse events.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection

Article Oncology

Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study

Peiliang Wang et al.

Summary: The study aimed to evaluate the safety and efficacy of anti-PD-1 agents combined with the novel multi-target tyrosine kinase inhibitor anlotinib in patients with advanced NSCLC. The results showed that the combination treatment had tolerable toxicity and favorable antitumor activity, with no additional toxicities observed.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma

Shenglong Li

Summary: Bone and soft tissue sarcomas are a small percentage of solid tumors in both children and adults, with various subtypes, and anlotinib, a novel oral tyrosine kinase inhibitor, has shown promising results in some cancer treatments.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)

Yihebali Chi et al.

Summary: In summary, the study showed that treatment with Anlotinib significantly prolonged progression-free survival in patients with refractory metastatic colorectal cancer, with improvements in objective response rate and disease control rate. However, overall survival was similar between the two groups.

ONCOLOGIST (2021)

Add to Collection

Review Biotechnology & Applied Microbiology

Recent Advances in Systemic Treatments for HER-2 Positive Advanced Gastric Cancer

Seda Kahraman et al.

Summary: Gastric cancer is the fifth most common cancer worldwide, with advanced cases being particularly difficult to cure. Treatment efforts focus on improving quality of life, tumor response rate, and survival while balancing therapy toxicities. The only available biomarkers for guiding treatment are HER2 overexpression, MSI/PD-L1 status, and FGFR alterations.

ONCOTARGETS AND THERAPY (2021)

Add to Collection

Article Oncology

Clinical Study of Sintilimab as Second-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Retrospective Study

Caiyun Nie et al.

Summary: The study demonstrates that sintilimab monotherapy or combination therapy is a feasible therapeutic option for patients with advanced or metastatic gastric cancer who have failed prior systemic therapies, with superior efficacy observed in the intestinal subtype compared to the non-intestinal subtype.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal